[Therapeutic value of trimetazidine in patients with coronary heart disease and left ventricular dysfunction].
OBJECTIVE
Trimetazidine has been shown to have anti-ischemic properties by improving exercise tolerance without haemodynamic effects and direct cyto-protective effects on the myocardium. The aim of this study was to assess the effect of trimetazidine on the treatment of patients with ischemic cardiomyopathy, and to assess the anti-angina efficacy and the clinical tolerance of TMZ.


METHODS
60 ischemic cardiomyopathy patients on conventional therapy were enrolled in this open multiple center clinical trial and received TMZ (20 mg 3 times per day) for six months. Patients were followed up for six months and assessments included clinical evaluation, electrocardiography and echocardiography.


RESULTS
All patients tolerated 60 mg of trimetazidine for six months, left ventricular ejection fraction (LVEF) was increased from 32.4 +/- 6.3% to 41.8 +/- 10.8% (P < 0.0001). Stage of NYHA classification was improved in most patients (P < 0.0001). Attack of angina was relieved and consumption of nitroglycerin reduced (both P < 0.001).


CONCLUSIONS
Trimetazidine seems to improve clinical status and ejection fraction, and reduce angina onsets without adverse effects in patients with ischemic cardiomyopathy.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003327:Coronary Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy*
D014665:Vasodilator Agents; D014292:Trimetazidine